Literature DB >> 1525046

Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein.

R Bouillon1, D Z Xiang, R Convents, H Van Baelen.   

Abstract

The affinity of purified human vitamin D-binding protein from serum (DBP) for 25-hydroxyvitamin D3 (25-OHD3) and 1 alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] was measured in the presence of free fatty acids (FFA), cholesterol, prostaglandins and several drugs. Mono- and polyunsaturated fatty acids markedly decreased the affinity of both 25-OHD3 and 1,25-(OH)2D3 for DBP, whereas saturated fatty acids (stearic and arachidic acid), cholesterol, cholesterol esters, retinol, retinoic acid and prostaglandins (A1 and E1) did not affect the apparent affinity. Several chemicals known to decrease the binding of thyroxine to its plasma-binding protein did not affect the affinity of DBP. The apparent affinity of DBP for both 25-OHD3 and 1,25-(OH)2D3 decreased 2.4- to 4.6-fold in the presence of 36 microM of linoleic or arachidonic acid, respectively. Only a molar ratio of FFA:DBP higher than 10,000 was able to decrease the binding of 25-OHD3 to DBP by 20%. Much smaller ratio's of FFA:DBP (25 for arachidonic and 45 for oleic acid), however, decreased the binding of 1,25-(OH)2D3 to DBP. These latter ratio's are well within the physiological range. The addition of human albumin in a physiological albumin:DBP molar ratio did not impair the inhibitory effect of linoleic acid on the binding of [3H]25-OHD3 to DBP. The binding and bioavailability of vitamin D metabolites thus might be altered by mono- and polyunsaturated but not by saturated fatty acids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525046     DOI: 10.1016/0960-0760(92)90094-y

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  16 in total

Review 1.  Current Controversies: Are Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D Status than Total Levels?

Authors:  Daniel D Bikle; Sofie Malmstroem; Janice Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12       Impact factor: 4.741

2.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

3.  Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP).

Authors:  A Kissmeyer; I S Mathiasen; S Latini; L Binderup
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

Review 4.  Vitamin D and DBP: the free hormone hypothesis revisited.

Authors:  Rene F Chun; Bradford E Peercy; Eric S Orwoll; Carrie M Nielson; John S Adams; Martin Hewison
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-04       Impact factor: 4.292

5.  Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis.

Authors:  Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

6.  Cross-talk among structural domains of human DBP upon binding 25-hydroxyvitamin D.

Authors:  Arjun Ray; Narasimha Swamy; Rahul Ray
Journal:  Biochem Biophys Res Commun       Date:  2007-11-21       Impact factor: 3.575

7.  Fatty acid-binding site environments of serum vitamin D-binding protein and albumin are different.

Authors:  Narasimha Swamy; Rahul Ray
Journal:  Bioorg Chem       Date:  2008-03-28       Impact factor: 5.275

8.  Vitamin D-binding protein controls T cell responses to vitamin D.

Authors:  Martin Kongsbak; Marina Rode von Essen; Trine Bøegh Levring; Peter Schjerling; Anders Woetmann; Niels Ødum; Charlotte Menné Bonefeld; Carsten Geisler
Journal:  BMC Immunol       Date:  2014-09-18       Impact factor: 3.615

9.  Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses.

Authors:  Louisa E Jeffery; Alice M Wood; Omar S Qureshi; Tie Zheng Hou; David Gardner; Zoe Briggs; Satdip Kaur; Karim Raza; David M Sansom
Journal:  J Immunol       Date:  2012-10-19       Impact factor: 5.422

Review 10.  Common variants of the vitamin D binding protein gene and adverse health outcomes.

Authors:  Suneil Malik; Lei Fu; David James Juras; Mohamed Karmali; Betty Y L Wong; Agnes Gozdzik; David E C Cole
Journal:  Crit Rev Clin Lab Sci       Date:  2013-02-22       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.